Bicalutamide (Casodex) in the treatment of prostate cancer (Q34293191)

1 August 2017

1 reference

title

Bicalutamide (Casodex) in the treatment of prostate cancer (English)

1 reference

1 August 2017

1 reference

1 reference

Yves Fradet

1

1 reference

1 August 2017

publication date

1 February 2004

1 reference

Expert Review of Anticancer Therapy

1 August 2017

published in

1 reference

1 August 2017

volume

4

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

37-48

1 reference

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Adjuvant and neoadjuvant hormonal therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Treatment options for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Relative potencies of flutamide and 'Casodex'

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Gynecomastia in patients with prostate cancer: a review of treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Bicalutamide dosages used in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Comparison of goserelin and leuprolide in combined androgen blockade therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

21 January 2018

Flutamide Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1586/14737140.4.1.37

21 January 2018

Identifiers

DOI

10.1586/14737140.4.1.37

1 reference

1 August 2017

1 reference